Denali Therapeutics Inc (DNLI)

$21.78 -0.96 (-4.22%)
Market Cap 3.19B
Revenue (ttm) 0.00
Net Income (ttm) -422.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,727,500
Avg Vol 1,672,384
Day's Range N/A - N/A
Shares Out 146.66M
Stochastic %K 61%
Beta 1.05
Analysts Strong Sell
Price Target $32.86

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Synd...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Address:
161 Oyster Point Boulevard, South San Francisco, United States
ZacksResearch
ZacksResearch Feb. 3 at 2:03 PM
Q4 earnings season — these 5 drug & biotech names could surprise to the upside $ZTS, $PCRX, $APLS, $ACAD, and $DNLI are highlighted as poised to beat on fourth-quarter 2025 earnings, setting up a potential outperformance theme investors should have on their radar. See which drug & biotech stocks could deliver earnings upside 👉 https://www.zacks.com/stock/news/2827958/5-drugbiotech-stocks-likely-to-outperform-q4-earnings-estimates?cid=sm-stocktwits-2-2827958-teaser-31624&ADID=SYND_STOCKTWITS_TWEET_2_2827958_TEASER_31624
0 · Reply
BullDonald
BullDonald Feb. 3 at 12:01 AM
$DNLI the PT is changing fast for good. Once it stabilizes above 23 the move to wards 30 is certain. M ready to add more.
0 · Reply
BullDonald
BullDonald Feb. 2 at 3:08 PM
$DNLI and $ETON in both my base price is the same. DNLI is already at MOON where are ETON kinda eating DUST, Zero movement and volume. seems we need to send some one to knock the door and ask any one is here to ETON Doors.
0 · Reply
BullDonald
BullDonald Jan. 30 at 5:19 PM
$DNLI Looking Great !
0 · Reply
PinTheInvestor
PinTheInvestor Jan. 30 at 2:04 PM
Hunter Syndrome is lining up nicely for $DNLI , particularly after $RGNX's AAV issues. The "continued DNL310 follow-up" presentation for on Thursday is icing. I am actually more interested in the Sanfilippo presentation. In these preliminary ph1/2 results we want to see safety (almost a given) and efficacy at the biomarker level (also very likely - qualitatively reported in Nov 2024). If they say *anything* about preserving development in the <28 mo cohort, that's a HUGE win. Fingers crossed for the stock and for the patient community.
0 · Reply
BullDonald
BullDonald Jan. 30 at 12:45 AM
$DNLI PRESSURE COOKER at this point.
0 · Reply
Eagley3k
Eagley3k Jan. 29 at 7:35 PM
$DNLI "Denali will present initial clinical data from the fully enrolled, ongoing Phase 1/2 study of DNL126 at the 2026 WORLDSymposiumTM (February 3-6, 2026). The Phase 1/2 study is designed to support an accelerated approval path in Sanfilippo syndrome Type A. Planning for a global Phase 3 confirmatory study is ongoing." Moving in anticipation of data readout next week. I see new highs on positive readout.
0 · Reply
BullDonald
BullDonald Jan. 29 at 6:11 PM
$DNLI This thing is a Blast.đź’Ą once crosses 23, Move towards 30 will start. Load the Boat.
0 · Reply
Daddy044
Daddy044 Jan. 29 at 12:32 PM
$IMMX A friend just told me about a Jeffries report that claimed approximately 72% of drugs with Breakthrough. The remaining roughly 43% fail because of missed primary endpoints not regulatory rejection. Names to watch include $IMMX, $BIIB, $BBIO, $DNLI, $AKRO (sold), $DYN$STOK$PRAX is a precision neuro trio.
1 · Reply
BullDonald
BullDonald Jan. 29 at 12:53 AM
$DNLI $30 is brewing ! here.
0 · Reply
Latest News on DNLI
Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Feb 2, 2026, 8:00 AM EST - 1 day ago

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Jan 29, 2026, 4:00 PM EST - 5 days ago

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 14, 2026, 12:45 AM EST - 20 days ago

Denali Therapeutics Inc. (DNLI) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Dec 30, 2025, 8:00 AM EST - 5 weeks ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Dec 10, 2025, 2:47 PM EST - 7 weeks ago

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Dec 10, 2025, 12:14 AM EST - 7 weeks ago

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Dec 9, 2025, 4:01 PM EST - 2 months ago

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript

Dec 5, 2025, 2:58 AM EST - 2 months ago

Denali Therapeutics Inc. (DNLI) Analyst/Investor Day Transcript

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:00 AM EST - 2 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

RPRX

Denali: Regulatory Delay Is A Strategic Opportunity

Dec 2, 2025, 8:09 AM EST - 2 months ago

Denali: Regulatory Delay Is A Strategic Opportunity

Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 22, 2025, 3:03 AM EST - 2 months ago

Denali Therapeutics Inc. (DNLI) Presents at Jefferies London Healthcare Conference 2025 Transcript

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:01 PM EST - 3 months ago

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

Oct 14, 2025, 2:43 PM EDT - 4 months ago

FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Oct 13, 2025, 4:01 PM EDT - 4 months ago

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 2:31 AM EDT - 5 months ago

Denali Therapeutics Inc. (DNLI) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 6 months ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Jul 7, 2025, 8:00 AM EDT - 7 months ago

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

May 6, 2025, 4:01 PM EDT - 9 months ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Apr 2, 2025, 8:00 AM EDT - 10 months ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 11 months ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN GPCR INSM MRK SWTX

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Mar 20, 2025, 2:16 PM EDT - 11 months ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Feb 6, 2025, 11:42 AM EST - 1 year ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 15, 2025, 2:26 PM EST - 1 year ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Jan 9, 2025, 3:56 PM EST - 1 year ago

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:43 PM EST - 1 year ago

Denali Therapeutics ALS drug fails in mid-stage trial

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Jan 6, 2025, 4:30 PM EST - 1 year ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Jan 3, 2025, 1:08 PM EST - 1 year ago

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 16, 2024, 8:56 AM EST - 1 year ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 6, 2024, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Aug 19, 2024, 10:55 PM EDT - 1 year ago

Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Aug 14, 2024, 2:00 PM EDT - 1 year ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 1, 2024, 6:45 AM EDT - 1 year ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

Jun 3, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

May 13, 2024, 12:30 PM EDT - 1 year ago

Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 4:01 PM EDT - 1 year ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

May 1, 2024, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Mar 6, 2024, 10:05 PM EST - 2 years ago

Denali: Leveraging Transport Vehicle Technology For Neurological Gains

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024, 8:05 AM EST - 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 27, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 7, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Feb 1, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Jan 8, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 7, 2023, 4:01 PM EST - 2 years ago

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Denali's New Summit: Changing Hunter Syndrome Landscape

Oct 2, 2023, 5:26 AM EDT - 2 years ago

Denali's New Summit: Changing Hunter Syndrome Landscape

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

Sep 11, 2023, 6:30 AM EDT - 2 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

FHTX MCRB MRNA SANA

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Aug 30, 2023, 8:30 AM EDT - 2 years ago

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 8, 2023, 4:01 PM EDT - 2 years ago

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

ZacksResearch
ZacksResearch Feb. 3 at 2:03 PM
Q4 earnings season — these 5 drug & biotech names could surprise to the upside $ZTS, $PCRX, $APLS, $ACAD, and $DNLI are highlighted as poised to beat on fourth-quarter 2025 earnings, setting up a potential outperformance theme investors should have on their radar. See which drug & biotech stocks could deliver earnings upside 👉 https://www.zacks.com/stock/news/2827958/5-drugbiotech-stocks-likely-to-outperform-q4-earnings-estimates?cid=sm-stocktwits-2-2827958-teaser-31624&ADID=SYND_STOCKTWITS_TWEET_2_2827958_TEASER_31624
0 · Reply
BullDonald
BullDonald Feb. 3 at 12:01 AM
$DNLI the PT is changing fast for good. Once it stabilizes above 23 the move to wards 30 is certain. M ready to add more.
0 · Reply
BullDonald
BullDonald Feb. 2 at 3:08 PM
$DNLI and $ETON in both my base price is the same. DNLI is already at MOON where are ETON kinda eating DUST, Zero movement and volume. seems we need to send some one to knock the door and ask any one is here to ETON Doors.
0 · Reply
BullDonald
BullDonald Jan. 30 at 5:19 PM
$DNLI Looking Great !
0 · Reply
PinTheInvestor
PinTheInvestor Jan. 30 at 2:04 PM
Hunter Syndrome is lining up nicely for $DNLI , particularly after $RGNX's AAV issues. The "continued DNL310 follow-up" presentation for on Thursday is icing. I am actually more interested in the Sanfilippo presentation. In these preliminary ph1/2 results we want to see safety (almost a given) and efficacy at the biomarker level (also very likely - qualitatively reported in Nov 2024). If they say *anything* about preserving development in the <28 mo cohort, that's a HUGE win. Fingers crossed for the stock and for the patient community.
0 · Reply
BullDonald
BullDonald Jan. 30 at 12:45 AM
$DNLI PRESSURE COOKER at this point.
0 · Reply
Eagley3k
Eagley3k Jan. 29 at 7:35 PM
$DNLI "Denali will present initial clinical data from the fully enrolled, ongoing Phase 1/2 study of DNL126 at the 2026 WORLDSymposiumTM (February 3-6, 2026). The Phase 1/2 study is designed to support an accelerated approval path in Sanfilippo syndrome Type A. Planning for a global Phase 3 confirmatory study is ongoing." Moving in anticipation of data readout next week. I see new highs on positive readout.
0 · Reply
BullDonald
BullDonald Jan. 29 at 6:11 PM
$DNLI This thing is a Blast.đź’Ą once crosses 23, Move towards 30 will start. Load the Boat.
0 · Reply
Daddy044
Daddy044 Jan. 29 at 12:32 PM
$IMMX A friend just told me about a Jeffries report that claimed approximately 72% of drugs with Breakthrough. The remaining roughly 43% fail because of missed primary endpoints not regulatory rejection. Names to watch include $IMMX, $BIIB, $BBIO, $DNLI, $AKRO (sold), $DYN$STOK$PRAX is a precision neuro trio.
1 · Reply
BullDonald
BullDonald Jan. 29 at 12:53 AM
$DNLI $30 is brewing ! here.
0 · Reply
BullDonald
BullDonald Jan. 28 at 9:56 PM
$DNLI Planning on Averaging UP again $VNDA Planning on Averaging UP again $ETON Hold $NRXP Watching
0 · Reply
Longbuy1
Longbuy1 Jan. 28 at 6:29 PM
$DNLI $RGNX it's saying that retail is stupid and sell your shares cheap,.
0 · Reply
Longbuy1
Longbuy1 Jan. 28 at 6:04 PM
$DNLI $RGNX DNL310 is in phase 2\3, screw your paid written article.
0 · Reply
prismmarketview
prismmarketview Jan. 28 at 5:54 PM
An FDA review delay and new safety overhang for Regenxbio’s (NASDAQ: $RGNX) RGX‑121 in Hunter syndrome are giving Denali’s Denali Therapeutics (NASDAQ: $DNLI) tividenofusp alfa a clearer shot at first‑to‑market status in this rare‑disease race. https://prismmarketview.com/fda-delay-for-regenxbio-may-open-the-door-for-denali-in-hunter-syndrome-race/
1 · Reply
dgbio
dgbio Jan. 28 at 5:41 PM
$DNLI Clinical hold on a somewhat competing product from Regenxbio should be seen as a somewhat positive for Denali. The difference in delivery mechanisms, AAV vector vs ERT, means no spillover impact on Denali's product.
0 · Reply
S_Franconi
S_Franconi Jan. 28 at 3:26 PM
$DNLI $IVA $CTMX
0 · Reply
lebranjames
lebranjames Jan. 28 at 12:41 PM
$DNLI take notes 📝 can’t afford a CRL like $RGNX
0 · Reply
BullDonald
BullDonald Jan. 26 at 1:39 PM
$DNLI we will see a move towards $30 here.
0 · Reply
onlyGreenPlz
onlyGreenPlz Jan. 25 at 8:09 AM
$DNLI Awaiting DNL310 PDUFA. Likely already priced in but looking for $30-35 range. Above that would be cherry on top.
0 · Reply
BullDonald
BullDonald Jan. 23 at 1:00 PM
$DNLI Did not expect it to move at this rate ... PT 30 is insight at this point.
0 · Reply
BullDonald
BullDonald Jan. 22 at 6:11 PM
$DNLI AVERAGED UP for the SECOND time Baby $ETON I need more of it. $VNDA I Love you too, AVERAGED UP Today $ESPR LOCO fiancials, No Touchy Touchy
0 · Reply
BullDonald
BullDonald Jan. 22 at 3:29 PM
$DNLI Just like that we are at $ 20 we will see $ 25 in weeks . Load the F up.
0 · Reply